全文获取类型
收费全文 | 1074906篇 |
免费 | 73390篇 |
国内免费 | 1371篇 |
专业分类
耳鼻咽喉 | 15033篇 |
儿科学 | 34677篇 |
妇产科学 | 28661篇 |
基础医学 | 153712篇 |
口腔科学 | 29586篇 |
临床医学 | 95026篇 |
内科学 | 203933篇 |
皮肤病学 | 24411篇 |
神经病学 | 81561篇 |
特种医学 | 43019篇 |
外国民族医学 | 204篇 |
外科学 | 163355篇 |
综合类 | 21737篇 |
现状与发展 | 1篇 |
一般理论 | 266篇 |
预防医学 | 74734篇 |
眼科学 | 24537篇 |
药学 | 86267篇 |
7篇 | |
中国医学 | 2817篇 |
肿瘤学 | 66123篇 |
出版年
2019年 | 7809篇 |
2018年 | 11377篇 |
2017年 | 8961篇 |
2016年 | 10158篇 |
2015年 | 11322篇 |
2014年 | 15370篇 |
2013年 | 22292篇 |
2012年 | 30674篇 |
2011年 | 32425篇 |
2010年 | 19031篇 |
2009年 | 17901篇 |
2008年 | 30048篇 |
2007年 | 32183篇 |
2006年 | 32802篇 |
2005年 | 31135篇 |
2004年 | 29811篇 |
2003年 | 28615篇 |
2002年 | 27595篇 |
2001年 | 60071篇 |
2000年 | 61514篇 |
1999年 | 50976篇 |
1998年 | 12456篇 |
1997年 | 11007篇 |
1996年 | 11024篇 |
1995年 | 10330篇 |
1994年 | 9350篇 |
1993年 | 8869篇 |
1992年 | 37803篇 |
1991年 | 36287篇 |
1990年 | 35751篇 |
1989年 | 34295篇 |
1988年 | 30876篇 |
1987年 | 30001篇 |
1986年 | 28223篇 |
1985年 | 26452篇 |
1984年 | 19188篇 |
1983年 | 16119篇 |
1982年 | 8831篇 |
1979年 | 17037篇 |
1978年 | 11407篇 |
1977年 | 10234篇 |
1976年 | 8843篇 |
1975年 | 10071篇 |
1974年 | 11652篇 |
1973年 | 11274篇 |
1972年 | 10756篇 |
1971年 | 10095篇 |
1970年 | 9255篇 |
1969年 | 8938篇 |
1968年 | 7917篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
T. Wu L. G. Trahair M. J. Bound C. F. Deacon M. Horowitz C. K. Rayner K. L. Jones 《Diabetic medicine》2015,32(5):595-600
53.
Harit Kapoor Kush Raj Lohani Tommy H. Lee Devendra K. Agrawal Sumeet K. Mittal 《CTS Clinical and Translational Science》2015,8(6):841-847
Esophageal adenocarcinoma is the fastest rising cancer in the United States. It develops from long‐standing gastroesophageal reflux disease which affects >20% of the general population. It carries a very poor prognosis with 5‐year survival <20%. The disease is known to sequentially progress from reflux esophagitis to a metaplastic precursor, Barrett''s esophagus and then onto dysplasia and esophageal adenocarcinoma. However, only few patients with reflux develop Barrett''s esophagus and only a minority of these turn malignant. The reason for this heterogeneity in clinical progression is unknown. To improve patient management, molecular changes which facilitate disease progression must be identified. Animal models can provide a comprehensive functional and anatomic platform for such a study. Rats and mice have been the most widely studied but disease homology with humans has been questioned. No animal model naturally simulates the inflammation to adenocarcinoma progression as in humans, with all models requiring surgical bypass or destruction of existing antireflux mechanisms. Valuable properties of individual models could be utilized to holistically evaluate disease progression. In this review paper, we critically examined the current animal models of Barrett''s esophagus, their differences and homologies with human disease and how they have shaped our current understanding of Barrett''s carcinogenesis. 相似文献
54.
Rohi Shah Nomaan Sheikh Jitendra Mangwani Nicolette Morgan Hamidreza Khairandish 《Journal of Clinical Orthopaedics and Trauma》2021,12(1):138
Demographic projections for hip fragility fractures indicate a rising annual incidence by virtue of a multimorbid, ageing population with more noncommunicable diseases (NCDs). NCDs are characterised by slow progression and long duration ranging from ischaemic cardiovascular disease, cerebrovascular disease, diabetes, chronic obstructive pulmonary disease to various cancers. Management of this disease burden often involves commencing patients on oral anticoagulants to reduce the risk of thromboembolic events. The use of direct oral anticoagulants (DOACs) in clinical practice has increased due to their rapid onset of action, short half-life and predictable anticoagulant effects, without the need for routine monitoring. Safe and timely surgical intervention relies on reversal of anticoagulants. However, the lack of specific evidence-based guidelines for the perioperative management of patients on DOACs with hip fractures has proved challenging; in particular, the accessibility of DOAC-specific assays, justification of the cost-benefit ratio of targeted reversal agents and indications for neuraxial anaesthesia. This has led to potentially avoidable delays in surgical intervention. Following a literature review of the pharmacokinetic and pharmacodynamics of commonly used DOACs in our region including the role of surrogate markers, we propose a systematic, evidence-based guideline to the perioperative management of hip fractures DOACs. We believe this standardised protocol can be easily replicated between hospitals. We recommend that if patients are deemed suitable for a general anaesthesia, with satisfactory renal function, optimal surgical time should be 24 h following the last ingested dose of DOAC. 相似文献
55.
56.
57.
58.
59.
60.